Search company, investor...

Founded Year

2017

Stage

Convertible Note - II | Alive

Total Raised

$5.34M

Last Raised

$920K | 1 yr ago

About Comphya

Comphya develops a therapy to restore erectile function. Comphya technology consists of implanting a neuro-stimulator in the pelvic cavity that selectively activates the nerve to trigger penile erections. The device provides self-controlled stimulation to the cavernous nerve to restore natural erectile function. The company was founded in 2017 and is based in Lausanne, Switzerland.

Headquarters Location

EPFL Innovation Park Bâtiment C

Lausanne, 1015,

Switzerland

+41.21.693.9517

Loading...

Loading...

Comphya Patents

Comphya has filed 2 patents.

The 3 most popular patent topics include:

  • implants (medicine)
  • penis
  • phosphodiesterase inhibitors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/11/2021

10/12/2021

Piperazines, Penis, Psychiatric diagnosis, Implants (medicine), Phosphodiesterase inhibitors

Grant

Application Date

2/11/2021

Grant Date

10/12/2021

Title

Related Topics

Piperazines, Penis, Psychiatric diagnosis, Implants (medicine), Phosphodiesterase inhibitors

Status

Grant

Latest Comphya News

Swiss medtech startups enter next development phase

Nov 29, 2023

Success 29.11.2023 Compremium, CoreMedic, Cutiss, Comphya and Novostia are making strides in the field of healthcare. Their solutions, addressing critical medical challenges from heart valve diseases to grave skin defects and erectile dysfunction, are currently being tested in humans. Based in Canton Berne, Compremium is developing diagnostic solutions for pressure-related conditions in the human body. Its platform technology is a non-invasive, portable and ultrasound-based solution, potentially making traditional invasive measurements of suspected ACS obsolete. In a recent study with 25 pediatric patients, the company’s pressure sensor, following the pressure-related ultrasound – PrUS – approach, was tested and showed promising results in measuring and managing soft tissue swelling after limb fractures. Swellings in a body’s anatomical compartment can lead to insufficient blood supply to tissue within that space, which poses a risk for a patient to develop acute compartment syndrome (ACS). The pressure sensor will have to be tested in larger cohorts to validate its practicality and performance in daily clinical settings. Cardiology company CoreMedic , based in Switzerland and Germany, announced the first successful transcatheter application of their ChordArt technology (ChordArt TMVr-System) in a First-in-Human trial for a patient suffering from severe degenerative mitral valve regurgitation (MR). The mitral valve leaflets do not close properly in patients with MR, causing blood to leak backwards across the valve, eventually leading to a shortage of blood moving to the rest of the body. MR is the most common type of heart valve disorders, affecting more than 25 million people worldwide. The ChordArt device is designed to enable safe and effective repair of the mitral valve by replacing damaged mitral valve chords with a conservatory physiological approach. CoreMedic is planning the next trial with more patients suffering from MR in a few months. Schlieren-based startup Cutiss , which focuses on skin regenerative medicine and tissue engineering, just closed the recruitment process for their denovoSkin phase II clinical trial in reconstructive surgery for children and adults. Conducted in Swiss, Italian and Dutch hospitals with 20 patients (one year and older), the study will test the safety and efficacy of a personalized, bio-engineered skin substitute – denovoSkin. The skin product is bio-egineered in large quantities originating from a post stamp sized piece of healthy skin. With a follow-up period of 3 years for patients, the first results could already be available within the next 12 months. In addition to this reconstructive surgical clinical trial, denovoSkin in adult and adolescent burn patients is currently transitioning towards phase III clinical trials in Switzerland and the EU, with Orphan Drug Designation for the treatment of burns from Swissmedic, European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). EPFL spin-off Comphya specializes in the treatment of erectile dysfunction in patients non-responsive to oral therapy. The startup developed and patented CaverSTIM, a neuro-stimulator which, when implanted in the pelvic cavity, will selectively activate the nerve to trigger penile erection. The device will provide self-controlled stimulation (via a wireless remote control) to the cavernous nerve to restore natural erectile function. The stimulator can be remotely operated by external controllers. In October, the startup has announced the first implantation of its CaverSTIM in spinal cord injury individuals. Following this initial success, additional surgeries are ongoing in collaboration with FMABC (Faculdade de Medicina do ABC) at two study centers, the Hospital Mario Covas and the Hospital do Servidor Publico de São Paulo in Brazil. Novostia is developing an artificial heart valve, TRIFLO, which is a unique valve made of high-performance biocompatible material that allows optimal blood flow, prevents the formation of clots and has great durability, while closing smoothly and silently. The Lausanne-based startup recently received the green light from the Lithuanian State Health Care Accreditation Agency to launch the First-in-Human trial to implant its aortic heart valve prosthesis, TRIFLO. This trial, scheduled to start in December 2023, will take place at Vilnius University Hospital Santaros Klinikos. Since its initiation in 2017, the TRIFLO project has been backed by positive and high-performance data in silico, in vitro and in vivo. The successful TRIFLO valve project is supported and co-financed by the EU through the EIC Accelerator program, by the Swiss Confederation through Innosuisse, and by the Canton of Vaud through the SPEI and the Biopôle. (Press release/ SR)

Comphya Frequently Asked Questions (FAQ)

  • When was Comphya founded?

    Comphya was founded in 2017.

  • Where is Comphya's headquarters?

    Comphya's headquarters is located at EPFL Innovation Park, Lausanne.

  • What is Comphya's latest funding round?

    Comphya's latest funding round is Convertible Note - II.

  • How much did Comphya raise?

    Comphya raised a total of $5.34M.

  • Who are the investors of Comphya?

    Investors of Comphya include Praxis Spinal Cord Institute, Foundation for Technological Innovation, IMD Startup Competition, Zurcher Kantonalbank, Verve Ventures and 7 more.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.